Researcher index
Authors in the psilocybin and psilocin literature
Search researcher names, inspect publication history, find recurring topics, and create author watch alerts without collecting unverified contact lists.
Publication history
A Phase 1b Study to Evaluate the Safety and Tolerability of MLS101 Treatment for Premenstrual Dysphoric Disorder (PMDD)ClinicalTrials.gov · 2026-11-05Psychedelics and psychosis: A systematic review of recent-era studies (1984-2025).Journal of psychopharmacology (Oxford, England) · 2026-10-27The Impact of Dose on the Impairing, Intoxicating, and Abuse-Related Effects of PsilocybinClinicalTrials.gov · 2026-10-16Reply to 'Methodological concerns and interpretative limitations of assessing subjective effects of ketamine'.Npj mental health research · 2026-09-22Psilocybin in the Treatment of Methamphetamine Use DisorderClinicalTrials.gov · 2026-09-21Who Is Reached by Supervised Psilocybin Services? Oregon Services Versus National Psilocybin UsemedRxiv · 2026-09-07AMCP Market Insights: Optimizing managed care approaches to treatment-resistant depression.Journal of managed care & specialty pharmacy · 2026-09-01Cardiovascular effects associated with acute recreational drug toxicity presentations to the emergency department: a European drug emergencies network (Euro-DEN plus) study.Clinical toxicology (Philadelphia, Pa.) · 2026-09-01A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10Classic psychedelics and personality: An updated systematic review.Journal of psychopharmacology (Oxford, England) · 2026-08-01Beyond Monoamines: Ketamine, Esketamine, and Classic Psychedelics in the Treatment of DepressionZenodo (CERN European Organization for Nuclear Research) · 2026-07-17Psilocybin-Assisted Early Palliative Care for Demoralization and Chronic Pain: An Open-Label Pilot Study.medRxiv: the preprint server for health sciences · 2026-07-14Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2)ClinicalTrials.gov · 2026-07-09Sustained Effects of Low-to-Moderate Doses of Psilocybin on Brain ConnectivitymedRxiv · 2026-04-20Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].Journal of affective disorders · 2026-01-15Development of Psilocybe Mushroom Species Reference Material-Cultivation Parameters and Chemical Profiles.Journal of AOAC International · 2026-01-01Toward Standardized Products Containing Biomass of Psilocybe Cubensis Fungi.Journal of AOAC International · 2026-01-01Pharmacological characterisation of psilocybin and 5-MeO-DMT discriminative cues in the rat and their translational value for identifying novel psychedelics.Journal of psychopharmacology (Oxford, England) · 2026-01-01Psychedelic therapy and postpartum depression: priorities and prospects.Therapeutic advances in psychopharmacology · 2026-01-01Phylogenomic systematics of (Boletaceae) reveals cryptic diversity, resolves global evolutionary relationships, and suggests a novel psychoactive lineage.Mycologia · 2026-01-01A Systematic Review of the efficacy, safety, and Tolerability of Psychedelics in the Treatment of post-traumatic Stress DisorderCurrent Treatment Options in Psychiatry · 2025-12-25Sex-specific role of the 5-HT receptor in psilocybin-induced extinction of opioid reward.Nature communications · 2025-11-20Long-term outcomes of single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - 12-month data from an open-label pilot study.Journal of affective disorders · 2025-11-15Publisher Correction: Psilocybin's lasting action requires pyramidal cell types and 5-HT2A receptors.Nature · 2025-10-01A critical evaluation of psilocybin-assisted therapy protocol components from clinical trial patients, facilitators, and caregivers.Psychotherapy (Chicago, Ill.) · 2025-09-01Set and setting of psychedelics for therapeutic use in psychiatry: A systematic review.Journal of psychopharmacology (Oxford, England) · 2025-09-01Global Increases in Brain Glucose Metabolism Following Acute N,N-Dimethyltryptamine and Harmine Administration in Healthy Volunteers: An [¹⁸F]FDG-PET StudyResearch Square · 2025-07-27Psilocybin's lasting action requires pyramidal cell types and 5-HT receptors.Nature · 2025-06-01Understanding the Psychological Effects of Psilocybin and 3,4-Methylenedioxymethamphetamine in a Non-Clinical PopulationmedRxiv · 2025-05-29Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2025-05-01Consistent evidence that brain serotonin 2A receptor binding is positively associated with personality-based risk markers of depression.The British journal of psychiatry: the journal of mental science · 2025-03-01The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.Journal of affective disorders · 2025-03-01A Modern Overview of the Potential Therapeutic Effects of Psilocybin in the Treatment of Depressive Disorders, Treatment-Resistant Depression, and End-of-Life Distress.Cureus · 2025-03-01Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper.European psychiatry: the journal of the Association of European Psychiatrists · 2025-01-10Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity.Neuropsychiatric disease and treatment · 2025-01-01Novel psychedelic interventions for post-traumatic stress disorder and their promise for precision medicine.Therapeutic advances in psychopharmacology · 2025-01-01Theoretical Description for Psilocin and Coprine Electrochemical Determination in Mushroom Pulp and Biological Liquids over Cobalt (II) Oxyhydroxide-Modified ElectrodeLetters in Applied NanoBioScience · 2024-12-30Pyramidal cell types and 5-HT receptors are essential for psilocybin's lasting drug action.bioRxiv: the preprint server for biology · 2024-11-03Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome.Npj mental health research · 2024-10-06Understanding Psychedelic-Assisted Psychotherapy Providers' Perspective and Insights: A Qualitative Analysis.Psychedelic medicine (New Rochelle, N.Y.) · 2024-09-01Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocolWellcome Open Res · 2024-07-24Structural pharmacology and therapeutic potential of 5-methoxytryptamines.Nature · 2024-06-01Comparing Neural Correlates of Consciousness: From Psychedelics to Hypnosis and Meditation.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2024-05-01Prefrontal Electrophysiological Biomarkers and Mechanism-Based Drug Effects in a Rat Model of Alcohol AddictionResearch Square · 2024-02-22Psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder: an fMRI pilot study.Scientific reports · 2024-02-07Behavioural Investigations of Psilocybin in Animals 1962-2021: A Scoping ReviewbioRxiv · 2024-01-05The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.Current neuropharmacology · 2024-01-01Trauma-Informed Care in Psychedelic Therapy Research: A Qualitative Literature Review of Evidence-Based Psychotherapy Interventions in PTSD and Psychedelic Therapy Across Conditions.Neuropsychiatric disease and treatment · 2024-01-01Corrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings.Frontiers in psychiatry · 2024-01-01Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: results from an open-label phase Ib ascending dose study.Headache · 2024-01-01Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol.Wellcome open research · 2024-01-01An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1).Pilot and feasibility studies · 2023-10-05Psychedelics promote plasticity by directly binding to BDNF receptor TrkB.Nature neuroscience · 2023-06-01Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life.Journal of affective disorders · 2023-04-14Safety and Efficacy of Psilocybin for Body Dysmorphic DisorderClinicalTrials.gov · 2023-03-13UNRAVELing the synergistic effects of psilocybin and environment on brain-wide immediate early gene expression in mice.bioRxiv: the preprint server for biology · 2023-02-21Use of Selective Alternative Therapies for Treatment of OCD.Neuropsychiatric disease and treatment · 2023-01-01Bedside to bench: the outlook for psychedelic research.Frontiers in pharmacology · 2023-01-01Predicting the Intensity of Psychedelic-Induced Mystical and Challenging Experience in a Healthy Population: An Exploratory Post-Hoc Analysis.Neuropsychiatric disease and treatment · 2023-01-01Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings.Frontiers in psychiatry · 2023-01-01Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.The New England journal of medicine · 2022-11-03Psilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language ProcessingPsyArXiv · 2022-09-30Association between Lifetime Classic Psychedelic Use and Sick Leave in a Population-Based Sample.International journal of environmental research and public health · 2022-09-09Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges.Expert opinion on drug safety · 2022-06-01Diversity, biology, and history of psilocybin-containing fungi: Suggestions for research and technological development.Fungal biology · 2022-04-01Effects of Ayahuasca on the Recognition of Facial Expressions of Emotions in Naive Healthy Volunteers: A Pilot, Proof-of-Concept, Randomized Controlled Trial.Journal of clinical psychopharmacology · 2021-01-01MDMA-induced changes in within-network connectivity contradict the specificity of these alterations for the effects of serotonergic hallucinogensNeuropsychopharmacology · 2020-11-19Long-term effects of psychedelic drugs: A systematic review.Neuroscience and biobehavioral reviews · 2020-06-01Scoping Review Protocol: Mapping Psilocybin Animal ResearchQueen's University QSpace · 2020-05-20Scoping Review Protocol: Mapping Psilocybin Therapy ResearchQueen's University QSpace · 2020-05-20[Addictions].Revue medicale suisse · 2020-01-15Reported effects of psychedelic use on those with low well-being given various emotional states and social contextsDrug Science Policy and Law · 2020-01-01Psychedelic microdosing benefits and challenges: an empirical codebook.Harm reduction journal · 2019-07-102018: A watershed year for psychedelic scienceDrug Science Policy and Law · 2019-01-01Serotonergic hallucinogens and recognition of facial emotion expressions: a systematic review of the literature.Therapeutic advances in psychopharmacology · 2019-01-01Microdosing Psychedelics: Personality, mental health, and creativity differences in microdosersPsyArXiv · 2018-11-02Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term MeditatorsClinicalTrials.gov · 2014-05-20Potential Therapeutic Effects of Psilocybin/Psilocin are Minimized While Possible Adverse Reactions are OverratedTherapeutic Drug Monitoring · 2014-02-01Fungal Hallucinogens Psilocin, Ibotenic Acid, and MuscimolTherapeutic Drug Monitoring · 2013-08-01Drugs of abuse monitoring in blood for control of driving under the influence of drugs.Therapeutic drug monitoring · 2002-04-01Profiles of psychedelic drugs. Psilocybin.Journal of psychedelic drugs · 1980-01-01Psilocin, Bufotenine and Serotonin: Historical and Biosynthetic ObservationsJournal of Psychedelic Drugs · 1979-01-01The Psilocybin Mushroom PandemicJournal of Psychedelic Drugs · 1975-01-01Psilocybin reactivity and time contraction as measured by psychomotor performance.Arzneimittel-Forschung · 1966-02-01[COMPARISON OF PSYCHOPHARMACA LSD-25, BOL-148 AND PSILOCYBIN IN CLINICAL PRACTICE].Vojnosanitetski pregled · 1963-05-01[OUR CLINICAL EXPERIENCE WITH A NEW PHARMACOLOGICAL PREPARATION PSILOCYBIN].Neuropsihijatrija · 1963-01-01